Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Abstract

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal transduction cascades or activate lethal receptors at the plasma membrane of cancer cells, they can opsonize neoplastic cells to initiate a tumor-targeting immune response, or they can be harnessed to specifically deliver toxins or radionuclides to transformed cells. As an indication of the success of this immunotherapeutic paradigm, international regulatory agencies approve new tumor-targeting mAbs for use in cancer patients every year. Moreover, the list of indications for previously licensed molecules is frequently expanded to other neoplastic disorders as the results of large, randomized clinical trials become available. Here, we discuss recent advances in the preclinical and clinical development of tumor-targeting mAbs for oncological indications.

• Authors: Erika Vacchelli, Jonathan Pol, Norma Bloy, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jérôme Galon, Aurélien Marabelle, Holbrook Kohrt, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
• Journal: Oncoimmunology (Oncoimmunology) Vol. 4 Issue 1 Pg. e985940 (Jan 2015) ISSN: 2162-4011 [Print] United States
• PMID: 25949870 (Publication Type: Review, Research Support, Non-U.S. Gov't)